Individual Patient Compassionate Use of Fedratinib
NCT03723148 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2020-09-18
Summary
This is an expanded access program (EAP) for eligible participants designed to provide access to fedratinib.
Expanded access is only available in markets where fedratinib is not yet approved.
Conditions
Interventions
- DRUG
-
Oral Fedratinib
Oral fedratinib administered as directed by treating physician.
Sponsors & Collaborators
-
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation
collaborator INDUSTRY -
Celgene
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia
NCT04543279 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
NCT04446650 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
NCT00706342 ·Status: COMPLETED ·Phase: PHASE2
-
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia
NCT01623167 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
NCT03194542 ·Status: COMPLETED ·Phase: PHASE2
-
Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia
NCT02055781 ·Status: TERMINATED ·Phase: PHASE3
-
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02076399 ·Status: COMPLETED ·Phase: PHASE3
-
Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
NCT01348490 ·Status: COMPLETED ·Phase: PHASE2
-
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
NCT05482971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
NCT03825783 ·Status: WITHDRAWN ·Phase: PHASE1
-
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
NCT03275740 ·Status: TERMINATED ·Phase: PHASE1
-
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
NCT02077192 ·Status: COMPLETED ·Phase: PHASE3
-
Thrombosomes® in Bleeding Thrombocytopenic Patients
NCT03394755 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
NCT01149681 ·Status: COMPLETED ·Phase: PHASE2
-
Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
NCT03922308 ·Status: COMPLETED ·Phase: PHASE2
-
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia
NCT01420783 ·Status: COMPLETED ·Phase: PHASE2
-
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
NCT02912208 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy
NCT00102323 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study of Eltrombopag for Promoting Thrombopoiesis After Total Body Irradiation
NCT00903929 ·Status: COMPLETED ·Phase: PHASE1
-
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
NCT01286038 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia
NCT02148133 ·Status: COMPLETED ·Phase: PHASE2
-
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
NCT00102336 ·Status: COMPLETED ·Phase: PHASE3
-
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
NCT04904276 ·Status: TERMINATED
-
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
NCT01882387 ·Status: WITHDRAWN ·Phase: PHASE2
-
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
NCT05143892 ·Status: UNKNOWN ·Phase: PHASE2